Waters (WAT) has seen an increase in demand from drugmakers in India as they accelerate efforts to develop generic versions of weight-loss drugs such as Novo Nordisk's (NVO) Wegovy and Ozempic, ahead of semaglutide's patent expiration in India next year, Reuters reported Thursday, citing a senior executive.
Indian drugmakers such as Biocon, Cipla, Dr. Reddy's, and Lupin are racing to develop generic versions of these drugs to grab a share of the projected $150 billion global market, the report said.
Waters expects double-digit revenue growth in India, contributing 70-100 basis points to annual growth, with GLP-1 drug testing alone adding 30 basis points in the near term, the report said.
Waters did not immediately respond to MT Newswires' request for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.